GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(38391)

  • GP10146 structure
    GP10146ferritin heavy chain fragment [Multiple species]
    Purity: >98%
  • GP22044 structure
    GP22044PAFAH2 Human
    Purity: >98%

    Platelet-Activating Factor Acetylhydrolase 2 Human Recombinant

  • GP23419 structure
    GP23419ESAT6
    Purity: Greater than 90.0% as determined by SDS-PAGE.

    Early Secretory Target Mycobacterium Tuberculosis Recombinant

  • GP23504 structure
    GP23504FLRT3 Human
    Purity: Greaterthan 90.0% as determined by SDS-PAGE.

    Fibronectin Leucine Rich Transmembrane Protein 3 Human Recombinant

  • GC15431 structure
    GC15431GF 109203X (Bisindolylmaleimide I)
    CAS: 133052-90-1
    Purity: >99.00%

    GF 109203X is a selective inhibitor of protein kinase C, selective for the α and β1 isoforms with IC 50 values of 0.0084, 0.0180, 0.210, 0.132, and 5.8μM for α, β1, δ, ε and ζ isoforms of protein kinase C respectively.

  • GC15520 structure
    GC15520Sotrastaurin (AEB071)
    CAS: 425637-18-9
    Purity: >99.50%

    Sotrastaurin (AEB071) is a potent and orally-active pan-protein kinase C (PKC) inhibitor, with Ki values of 0.22nM, 0.64nM, 0.95nM, 1.8nM, 2.1nM and 3.2nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively.

  • GC16907 structure
    GC16907Go 6983
    CAS: 133053-19-7
    Purity: >99.00%

    Go 6983 is a pan-PKC inhibitor that acts on PKCα, PKCβ, PKCγ, PKCδ, andPKCμ with IC 50 values of 7nM, 7nM, 6nM, 10nM, and 20μM, respectively.

  • GC13655 structure
    GC13655LDE225 (NVP-LDE225,Erismodegib)
    CAS: 956697-53-3
    Purity: >99.50%

    LDE225 (NVP-LDE225,Erismodegib) (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively.

  • GC16388 structure
    GC16388Odanacatib (MK-0822)
    CAS: 603139-19-1
    Purity: >98.00%

    Odanacatib (MK-0822) is an orally active inhibitor of cathepsin K.

  • GC12407 structure
    GC12407Z-IETD-FMK
    CAS: 210344-98-2
    Purity: >98.00%

    Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell-permeable inhibitor of caspase-8.

  • GC15963 structure
    GC15963Nu 6027
    CAS: 220036-08-8
    Purity: >99.00%

    ATR/CDK inhibitor, potent and selective

  • GC16990 structure
    GC16990Z-LEHD-FMK
    CAS: 210345-04-3
    Purity: >98.00%

    Z-LEHD-FMK is an irreversible caspase-9 inhibitor.

  • GC17052 structure
    GC17052MK-4827 Racemate
    CAS: 1038915-75-1
    Purity: >98%

    selective inhibitor of PARP1/PARP2

  • GC10011 structure
    GC10011SDM25N hydrochloride
    CAS: 342884-71-3
    Purity: >98%

    δ receptor antagonist

  • GC10050 structure
    GC10050Almorexant hydrochloride
    CAS: 913358-93-7
    Purity: >99.00%

    OX1R/OX2R antagonist

  • GC10059 structure
    GC10059Endomorphin-2
    CAS: 141801-26-5
    Purity: >98%

    Endomorphin-2 is a high-affinity and highly selective agonist of the μ-opioid receptor (K i = 0.69nM).

  • GC10209 structure
    GC10209TAK-733
    CAS: 1035555-63-5
    Purity: >99.00%

    MEK allosteric site inhibitor

  • GC10333 structure
    GC10333DPDPE
    CAS: 88373-73-3
    Purity: >98%

    DPDPE is a selective and anticonvulsant δ-opioid receptor (DOR) agonist.

  • GC10583 structure
    GC10583WAY-600
    CAS: 1062159-35-6
    Purity: >98%

    MTOR inhibitor

  • GC10717 structure
    GC10717Almorexant
    CAS: 871224-64-5
    Purity: >99.00%

    OX1R/OX2R antagonist

  • GC10803 structure
    GC10803DAMGO
    CAS: 78123-71-4
    Purity: >99.50%

    DAMGO is a highly selective peptide agonist for the μ-opioid receptor (MOR) with a Kd of 3.46nM.

  • GC10807 structure
    GC10807PL 017
    CAS: 83397-56-2
    Purity: >98%

    Selective μ opioid receptor agonist

  • GC10924 structure
    GC10924Btk inhibitor 1 R enantiomer
    CAS: 1022150-12-4
    Purity: >99.00%

    Btk inhibitor 1 R enantiomer is an impurity of Ibrutinib. Btk inhibitor 1 R enantiomer can be used in synthesis of Btk inhibitor 1 R enantiomer Ibrutinib dimer and Btk inhibitor 1 R enantiomer adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.

  • GC11211 structure
    GC11211Terbutaline Sulfate
    CAS: 23031-32-5
    Purity: >99.50%

    Selective β2-adrenergic receptor agonist